AIMS: The aim of the present study was to investigate whether selective antagonism of the cysteine-X-cysteine chemokine receptor-2 (CXCR2) receptor has any adverse effects on the key innate effector functions of human neutrophils for defence against microbial pathogens. METHODS: In a double-blind, crossover study, 30 healthy volunteers were randomized to treatment with the CXCR2 antagonist AZD5069 (100 mg) or placebo, twice daily orally for 6 days. The peripheral blood neutrophil count was assessed at baseline, daily during treatment and in response to exercise challenge and subcutaneous injection of granulocyte-colony stimulating factor (G-CSF). Neutrophil function was evaluated by phagocytosis of Escherichia coli and by the oxidative burst response to E. coli. RESULTS: AZD5069 treatment reversibly reduced circulating neutrophil count from baseline by a mean [standard deviation (SD)] of -1.67 (0.67) ×10(9) l(-1) vs. 0.19 (0.78) ×10(9) l(-1) for placebo on day 2, returning to baseline by day 7 after the last dose. Despite low counts on day 4, a 10-min exercise challenge increased absolute blood neutrophil count, but the effect with AZD5069 was smaller and not sustained, compared with placebo treatment. Subcutaneous G-CSF on day 5 caused a substantial increase in blood neutrophil count in both placebo- and AZD5069-treated subjects. Superoxide anion production in E. coli-stimulated neutrophils and phagocytosis of E. coli were unaffected by AZD5069 (P = 0.375, P = 0.721, respectively vs. baseline, Day 4). AZD5069 was well tolerated. CONCLUSIONS: CXCR2 antagonism did not appear adversely to affect the mobilization of neutrophils from bone marrow into the peripheral circulation, phagocytosis or the oxidative burst response to bacterial pathogens. This supports the potential of CXCR2 antagonists as a treatment option for diseases in which neutrophils play a pathological role.
RCT Entities:
AIMS: The aim of the present study was to investigate whether selective antagonism of the cysteine-X-cysteine chemokine receptor-2 (CXCR2) receptor has any adverse effects on the key innate effector functions of human neutrophils for defence against microbial pathogens. METHODS: In a double-blind, crossover study, 30 healthy volunteers were randomized to treatment with the CXCR2 antagonist AZD5069 (100 mg) or placebo, twice daily orally for 6 days. The peripheral blood neutrophil count was assessed at baseline, daily during treatment and in response to exercise challenge and subcutaneous injection of granulocyte-colony stimulating factor (G-CSF). Neutrophil function was evaluated by phagocytosis of Escherichia coli and by the oxidative burst response to E. coli. RESULTS:AZD5069 treatment reversibly reduced circulating neutrophil count from baseline by a mean [standard deviation (SD)] of -1.67 (0.67) ×10(9) l(-1) vs. 0.19 (0.78) ×10(9) l(-1) for placebo on day 2, returning to baseline by day 7 after the last dose. Despite low counts on day 4, a 10-min exercise challenge increased absolute blood neutrophil count, but the effect with AZD5069 was smaller and not sustained, compared with placebo treatment. Subcutaneous G-CSF on day 5 caused a substantial increase in blood neutrophil count in both placebo- and AZD5069-treated subjects. Superoxide anion production in E. coli-stimulated neutrophils and phagocytosis of E. coli were unaffected by AZD5069 (P = 0.375, P = 0.721, respectively vs. baseline, Day 4). AZD5069 was well tolerated. CONCLUSIONS:CXCR2 antagonism did not appear adversely to affect the mobilization of neutrophils from bone marrow into the peripheral circulation, phagocytosis or the oxidative burst response to bacterial pathogens. This supports the potential of CXCR2 antagonists as a treatment option for diseases in which neutrophils play a pathological role.
Authors: S E Wenzel; L B Schwartz; E L Langmack; J L Halliday; J B Trudeau; R L Gibbs; H W Chu Journal: Am J Respir Crit Care Med Date: 1999-09 Impact factor: 21.405
Authors: Coralie Martin; Peter C E Burdon; Gary Bridger; Jose Carlos Gutierrez-Ramos; Timothy J Williams; Sara M Rankin Journal: Immunity Date: 2003-10 Impact factor: 31.745
Authors: Astrid E Cardona; Margaret E Sasse; Liping Liu; Sandra M Cardona; Makiko Mizutani; Carine Savarin; Taofang Hu; Richard M Ransohoff Journal: Blood Date: 2008-03-17 Impact factor: 22.113
Authors: Janesh Pillay; Bart P Ramakers; Vera M Kamp; Adele Lo Tam Loi; Siu W Lam; Falco Hietbrink; Luke P Leenen; Anton T Tool; Peter Pickkers; Leo Koenderman Journal: J Leukoc Biol Date: 2010-04-16 Impact factor: 4.962
Authors: Lillian Sun; Paul E Clavijo; Yvette Robbins; Priya Patel; Jay Friedman; Sarah Greene; Rita Das; Chris Silvin; Carter Van Waes; Lucas A Horn; Jeffrey Schlom; Claudia Palena; Dean Maeda; John Zebala; Clint T Allen Journal: JCI Insight Date: 2019-04-04
Authors: Dhiren F Patel; Teresa Peiró; Nicoletta Bruno; Juho Vuononvirta; Samia Akthar; Franz Puttur; Chloe J Pyle; Kornelija Suveizdytė; Simone A Walker; Aran Singanayagam; Leo M Carlin; Lisa G Gregory; Clare M Lloyd; Robert J Snelgrove Journal: Sci Immunol Date: 2019-11-08
Authors: Carina Kärrman Mårdh; James Root; Mohib Uddin; Kristina Stenvall; Anna Malmgren; Kostas Karabelas; Matthew Thomas Journal: J Immunol Res Date: 2017-05-15 Impact factor: 4.818